10.15 USD
+0.02 (+0.2%)
10.17 USD
+0.02 (+0.2%)
We assign a fundamental rating of 3 out of 10 to ITOS. ITOS was compared to 533 industry peers in the Biotechnology industry. ITOS has a great financial health rating, but its profitability evaluates not so good. ITOS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ITOS has reported negative net income.
In the past year ITOS has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ITOS reported negative net income in multiple years.
ITOS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -21.57%, ITOS is in the better half of the industry, outperforming 75.83% of the companies in the same industry.
ITOS has a Return On Equity of -27.22%. This is in the better half of the industry: ITOS outperforms 79.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.57% | ||
| ROE | -27.22% | ||
| ROIC | N/A |
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ITOS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ITOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ITOS has been increased compared to 1 year ago.
Compared to 5 years ago, ITOS has more shares outstanding
ITOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 1.90 indicates that ITOS is not a great score, but indicates only limited risk for bankruptcy at the moment.
ITOS has a better Altman-Z score (1.90) than 66.79% of its industry peers.
There is no outstanding debt for ITOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.9 |
ROIC/WACCN/A
WACC9.73%
2.3 Liquidity
ITOS has a Current Ratio of 7.53. This indicates that ITOS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.53, ITOS is in the better half of the industry, outperforming 71.40% of the companies in the same industry.
A Quick Ratio of 7.53 indicates that ITOS has no problem at all paying its short term obligations.
The Quick ratio of ITOS (7.53) is better than 71.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.53 | ||
| Quick Ratio | 7.53 |
3. Growth
3.1 Past
The earnings per share for ITOS have decreased strongly by -43.67% in the last year.
ITOS shows a strong growth in Revenue. In the last year, the Revenue has grown by 177.89%.
Measured over the past years, ITOS shows a very negative growth in Revenue. The Revenue has been decreasing by -53.35% on average per year.
EPS 1Y (TTM)-43.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-694.44%
Revenue 1Y (TTM)177.89%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to grow by 3.35% on average over the next years.
Based on estimates for the next years, ITOS will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-7.51%
EPS Next 2Y17.23%
EPS Next 3Y13.13%
EPS Next 5Y3.35%
Revenue Next Year-100%
Revenue Next 2Y-61.63%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ITOS. In the last year negative earnings were reported.
Also next year ITOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ITOS's earnings are expected to grow with 13.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.23%
EPS Next 3Y13.13%
5. Dividend
5.1 Amount
No dividends for ITOS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10.15
+0.02 (+0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners104.81%
Inst Owner Change-99.52%
Ins Owners1.18%
Ins Owner Change-16.18%
Market Cap448.73M
Revenue(TTM)35.00M
Net Income(TTM)-134.41M
Analysts50
Price Target10.56 (4.04%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.81%
Min EPS beat(2)-39.15%
Max EPS beat(2)17.53%
EPS beat(4)2
Avg EPS beat(4)-8.08%
Min EPS beat(4)-39.15%
Max EPS beat(4)17.53%
EPS beat(8)6
Avg EPS beat(8)14.15%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.92%
PT rev (3m)-11.92%
EPS NQ rev (1m)-6.61%
EPS NQ rev (3m)-10.11%
EPS NY rev (1m)-10.29%
EPS NY rev (3m)-1.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12.82 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.91 | ||
| P/tB | 0.91 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.31
EYN/A
EPS(NY)-2.08
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.44
OCFYN/A
SpS0.79
BVpS11.17
TBVpS11.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.57% | ||
| ROE | -27.22% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 52.87% | ||
| Cap/Sales | 1.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.53 | ||
| Quick Ratio | 7.53 | ||
| Altman-Z | 1.9 |
F-Score3
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)204.25%
Cap/Depr(5y)178.55%
Cap/Sales(3y)9.83%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-694.44%
EPS Next Y-7.51%
EPS Next 2Y17.23%
EPS Next 3Y13.13%
EPS Next 5Y3.35%
Revenue 1Y (TTM)177.89%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-61.63%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-5.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.37%
OCF growth 3YN/A
OCF growth 5YN/A
ITEOS THERAPEUTICS INC / ITOS FAQ
What is the fundamental rating for ITOS stock?
ChartMill assigns a fundamental rating of 3 / 10 to ITOS.
What is the valuation status of ITEOS THERAPEUTICS INC (ITOS) stock?
ChartMill assigns a valuation rating of 0 / 10 to ITEOS THERAPEUTICS INC (ITOS). This can be considered as Overvalued.
What is the profitability of ITOS stock?
ITEOS THERAPEUTICS INC (ITOS) has a profitability rating of 1 / 10.
How financially healthy is ITEOS THERAPEUTICS INC?
The financial health rating of ITEOS THERAPEUTICS INC (ITOS) is 7 / 10.
What is the expected EPS growth for ITEOS THERAPEUTICS INC (ITOS) stock?
The Earnings per Share (EPS) of ITEOS THERAPEUTICS INC (ITOS) is expected to decline by -7.51% in the next year.